Targeted Oncology Staff

Treatment-naïve patients with chronic lymphocytic leukemia who had comorbidities saw a reduction in the risk of disease progression or death after treatment with venetoclax combined with obinutuzumab versus obinutuzumab plus chlorambucil.

Based on data from the phase III TAGS trial, a supplemental new drug application seeking approval for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction, has been granted a priority review by the FDA.

Patients with advanced or metastatic renal cell carcinoma who were treated with the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) demonstrated a significantly improved survival benefit compared with sunitinib (Sutent) in the first-line setting, meeting the endpoints of the pivotal phase III KEYNOTE-426 trial.

Gardasil 9 (HPV 9-valent Vaccine, Recombinant), a vaccine for the prevention of HPV, has been approved by the FDA for use in males and females aged 9 through 45 years.

A new drug application for selinexor has been granted a priority review by the FDA as a treatment for patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the agent.

ASCO has revealed its first clinical trial, which will provide patients with limited options an opportunity to receive a potentially beneficial targeted therapy that matches their distinct genetic make-up and is FDA-approved for another type of cancer.